25I-NBOMe
| Clinical data | |
|---|---|
| Other names | 2C-I-NBOMe; 25I-NB2OMe; 25I; 25i; N-Bomb; Smiles; Wizard; INBMeO; Cimbi-5; Cimbi-5-2; N-(2-Methoxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine; 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine |
| Routes of administration | Mainly sublingual, buccal, and insufflation[1] |
| Drug class | Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen[1] |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Very low[1] |
| Metabolism | Extensive first-pass metabolism in the liver[1] |
| Onset of action | 15–120 min (0.25–2 hours)[1] |
| Duration of action | Insufflation: 4–6 h[1] Sublingual: 6–10 h[1] Buccal: 6–10 h[1] |
| Excretion | Urine[1] |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H22INO3 |
| Molar mass | 427.282 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
25I-NBOMe, also known as 2C-I-NBOMe, Cimbi-5, and shortened to "25I", is a psychedelic drug of the phenethylamine, 2C, and NBOMe (25-NB) families.[1] Since 2010, it has circulated in the recreational drug scene, often misrepresented as LSD.[6] It is the most well-known member of the 25-NB family and the earliest member to be encountered as a novel recreational drug.[6]
The carbon-11 labelled version of 25I-NBOMe, [11C]Cimbi-5, was synthesized and validated as a radiotracer for positron emission tomography (PET) in Copenhagen.[7][8] Being the first 5-HT2A receptor full agonist PET radioligand, [11C]CIMBI-5 shows promise as a more functional marker of these receptors, particularly in their high affinity states.[7]
Street and media nicknames for this drug include "N-Bomb", "Solaris", "Smiles", and "Wizard", although the drug is frequently fraudulently sold as LSD.[1][9][10][11]
Due to its physical effects and risk of overdose, there have been multiple deaths attributed to the drug.[1] Its long-term toxicity is unknown due to lack of existing research.
25I-NBOMe was first described in 2000.[12][13][14] It was first encountered as a novel recreational drug in 2010, and by 2012, NBOMes like 25I-NBOMe had surpassed other major psychedelics like LSD and psilocybin-containing mushrooms in popularity, at least for a time.[15][16][17][18] 25I-NBOMe became a controlled substance in the United States in 2013.[15]
- ^ a b c d e f g h i j k l Nikolaou P, Papoutsis I, Stefanidou M, Spiliopoulou C, Athanaselis S (January 2015). "2C-I-NBOMe, an "N-bomb" that kills with "Smiles". Toxicological and legislative aspects". Drug Chem Toxicol. 38 (1): 113–119. doi:10.3109/01480545.2014.911882. PMID 24785196.
- ^ Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
- ^ "Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". Canada Gazette. 4 May 2016. Archived from the original on 2016-08-31. Retrieved 2016-08-22.
- ^ UK Home Office (2014). "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Government. Archived from the original on 2014-12-04. Retrieved 2014-03-11.
- ^ "Substance Details 25I-NBOMe". Archived from the original on 2024-01-23. Retrieved 2024-01-23.
- ^ a b Herian M, Wojtas A, Kamińska K, Świt P, Wach A, Gołembiowska K (July 2019). "Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats". Neurotox Res. 36 (1): 91–100. doi:10.1007/s12640-019-00033-x. PMC 6570696. PMID 30989482.
The NBOMes became available to drug users when they first appeared on the drug market in 2010, with 25I-NBOMe emerging as the earliest (Halberstadt 2017; Poklis et al. 2015; Zuba et al. 2013).
- ^ a b Ettrup A, Palner M, Gillings N, Santini MA, Hansen M, Kornum BR, et al. (November 2010). "Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET". Journal of Nuclear Medicine. 51 (11): 1763–1770. doi:10.2967/jnumed.109.074021. PMID 20956470.
- ^ Hansen M (16 December 2010). "Design and synthesis of selective serotonin receptor agonists for positron emission tomography imaging of the brain". Ph.D. Thesis. Det Farmaceutiske Fakultet, København. CiteSeerX 10.1.1.690.4529.
- ^ "Erowid 25I-NBOMe Vault". Archived from the original on 2016-06-30. Retrieved 2016-06-28.
- ^ Vanderbilt University Medical Center (9 April 2015). "Poison center warns against designer drug 'N-bomb'". ScienceDaily. Archived from the original on 9 May 2016. Retrieved 14 April 2016.
- ^ Mackin, Teresa (October 9, 2012). Dangerous synthetic drug making its way across the country. Archived October 31, 2012, at the Wayback Machine WISH-TV
- ^ Cite error: The named reference
HeimElz2000was invoked but never defined (see the help page). - ^ Cite error: The named reference
PertzHeimElz2000was invoked but never defined (see the help page). - ^ Cite error: The named reference
Heim2003was invoked but never defined (see the help page). - ^ a b Poulie CB, Jensen AA, Halberstadt AL, Kristensen JL (December 2020). "DARK Classics in Chemical Neuroscience: NBOMes". ACS Chem Neurosci. 11 (23): 3860–3869. doi:10.1021/acschemneuro.9b00528. PMC 9191638. PMID 31657895.
- ^ Cite error: The named reference
WoodSedefovCunningham2015was invoked but never defined (see the help page). - ^ Cite error: The named reference
Morgans2017was invoked but never defined (see the help page). - ^ Cite error: The named reference
LawnBarrattWilliamswas invoked but never defined (see the help page).